Revenue ($USD) : $492,681,000
R&D spend : $60,244,000
Employees : 2,000
Fiscal year end : 12/31/2023
CEO : Quentin Blackford

www.irhythmtech.com

Wearable cardiac monitor maker iRhythm began 2024 with a CE mark for its next-generation Zio ECG system and its Zeus AI algorithm, followed by a $661 million debt offering. However, despite progress remediating problems from an FDA warning letter received in May 2023, the company disclosed more FDA inspection issues in August. That same month, CFO Brice Bobzien submitted his resignation for personal reasons. Daniel Wilson starts as CFO on Aug. 31. –SW